The presentation signals a shift in fasedienol's registrational strategy from SUDS-based public speaking challenge to LSAS-based everyday-life assessment. Monitor for FDA feedback on the proposed Phase 3 design, which is the key near-term catalyst. No financial data or timeline for the next study was provided.
Price Chart
Executive Summary
Vistagen filed an 8-K furnishing a new corporate presentation (Exhibit 99.1) that outlines its pipeline, clinical data, and proposed regulatory path for fasedienol in social anxiety disorder. The presentation details a planned single Phase 3 study using the LSAS endpoint in everyday-life settings, supported by post-hoc and open-label data, but contains no new financial results, guidance, or definitive regulatory milestones.
Key Facts
- Filing is a routine 8-K (Item 7.01) furnishing a corporate presentation — no new financial data or material definitive agreement.
- Lead candidate fasedienol: PALISADE-2 met primary endpoint (p=0.015); PALISADE-1, -3, -4 did not achieve statistical significance on primary endpoints.
- Proposed next step: single Phase 3 LSAS-based study (N=350, 6-week double-blind) in everyday-life setting, to be finalized based on FDA feedback.
- Post-hoc analysis of very severe SAD subjects in PALISADE-4 showed nominally significant SUDS improvement vs placebo (p=0.036).
- Pipeline includes itruvone (MDD, Phase 2b planned), refisolone (menopausal hot flashes/PMDD, Phase 2a PoC), PH15 (cognitive impairment), PH284 (cancer cachexia).
- No revenue, EPS, cash position, or guidance figures disclosed in the filing.
Financial Impact
No financial figures reported in the filing.
Risk Factors
- Only one of four Phase 3 PALISADE trials met its primary endpoint; three failed on SUDS.
- Proposed Phase 3 LSAS study design is not finalized and depends on FDA feedback — regulatory risk remains high.
- Post-hoc and exploratory analyses may not replicate in adequately powered trials.
- Company is pre-revenue with no approved products; requires financing for continued operations.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-063510 |
| Document: vtgn-20260925.htm | 0001628280-26-063510 |
| Document: 0001628280-26-063510-index-headers.html | 0001628280-26-063510 |
| Document: 0001628280-26-063510-index.html | 0001628280-26-063510 |
| Document: 0001628280-26-063510.txt | 0001628280-26-063510 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $0.2300 $0.2000 | ▼ −13.04% | ▼ −11.55% | $0.1740 (−24.35%) |
Sep 25, 2026 4w ago | 8-K | $0.2700 $0.2800 | ▲ +3.70% | ▲ +3.93% | $0.1740 (−35.56%) |
Sep 24, 2026 4w ago | 8-K | $0.2950 $0.2826 | ▼ −4.20% | ▼ −3.79% | $0.1740 (−41.02%) |
Sep 24, 2026 4w ago | Press Release | $0.2950 $0.2826 | ▼ −4.20% | ▼ −3.79% | $0.1740 (−41.02%) |
Aug 14, 2026 10w ago | 8-K | $0.2676 $0.2440 | ▲ +8.82% | ▲ +7.45% | $0.1740 (+34.98%) |
Aug 14, 2026 10w ago | Press Release | $0.2676 $0.2440 | ▼ −8.82% | ▼ −7.45% | $0.1740 (−34.98%) |
Jul 31, 2026 12w ago | 8-K | $0.2410 $0.2876 | ▲ +19.34% | ▲ +15.82% | $0.1740 (−27.80%) |
Jun 30, 2026 17w ago | 8-K | $0.2260 $0.2458 | ▼ −8.76% | ▼ −8.16% | $0.1740 (+23.01%) |
Jun 17, 2026 18w ago | 8-K | $0.6702 $0.6166 | ▼ −8.00% | ▼ −6.33% | $0.1740 (−74.04%) |
Jun 15, 2026 19w ago | 8-K | $0.6900 $0.6323 | ▼ −8.36% | ▼ −6.13% | $0.1740 (−74.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers